Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
Provided By GlobeNewswire
Last update: Sep 8, 2025
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, Inc. (Nasdaq: IMDX), (“iMDx”), today announced a positive strategic update and novel registry that will serve to gather real-world data on patient experiences and outcomes regarding its flagship kidney transplant rejection assay.
Read more at globenewswire.com
